Advertisement

Investigational New Drugs

, Volume 26, Issue 6, pp 489–504 | Cite as

Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors

  • Manu JaggiEmail author
  • Sudhanand Prasad
  • Anu T. Singh
  • R. Praveen
  • Sarjana Dutt
  • Archana Mathur
  • Rajan Sharma
  • Neena Gupta
  • Rinku Ahuja
  • Rama Mukherjee
  • Anand C. Burman
PRECLINICAL STUDIES

Summary

A novel peptide combination consisting of four synthetic neuropeptide analogs of Vasoactive Intestinal Peptide (VIP), Bombesin, Substance P and Somatostatin has been found to have potent anticancer activity in vitro and in vivo. The receptors of these four neuropeptides are known to be over expressed in various cancers. We have found the presence of native neuropeptides in the culture supernatant of the primary tumor cells of human colon adenocarcinomas. It was further demonstrated by receptor-ligand assays that not only do these tumor cells synthesize and secrete four peptide hormones but also possess specific high affinity receptors on their surface. Screening a large panel of analogs to the four peptide hormones on tumor cell proliferation led to the identification of four cytotoxic analogs, the combination of which was code-named DRF7295. The design and synthesis of the peptide analogs have been described in this paper. In vitro anticancer activity of DRF7295 was studied in a large panel of human tumor cells. Gastrointestinal tumor cells of the colon, pancreas and duodenum were found to be most sensitive to DRF7295 with moderate activity seen in glioblastoma, prostate, leukemia and those of oral cancer cells. Efficacy studies in xenograft models of colon and duodenum resulted in T/C% of less than 40%, which is indicative of strong tumor regressing potential of DRF7295 in gastrointestinal cancers. Acute and long-term toxicity studies as well as safety pharmacology studies conducted indicate the safety of the drug upon systemic administration with no significant adverse pharmacological effects.

Keywords

Neuropeptides Gastrointestinal cancer Peptide design Cytotoxicity Xenograft Long-term safety 

Notes

Acknowledgement

This project was partly funded by Department of Science & Technology, Ministry of Science, Government of India.

References

  1. 1.
    Burbach JP, Meijer OC (1992) The structure of neuropeptide receptors. Eur J Pharmacol 227:1–18PubMedCrossRefGoogle Scholar
  2. 2.
    Rozengurt E (1996) Neuropeptides growth factors: signaling pathways and role in cancer. In: Pusztai LL, Lewis CE, Yap E (eds) Cell proliferation in cancer: regulatory mechanisms of neoplastic cell growth. Oxford University press, New York, pp 247–259Google Scholar
  3. 3.
    Favoni RE, De Cupis A (2000) The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach. Pharmacol Rev 52:179–206PubMedGoogle Scholar
  4. 4.
    Pimentel (1994) Growth factors and neoplasia. In: Handbook of Growth factors, vol. 1. CRC, USA, pp 329–337Google Scholar
  5. 5.
    Matsumoto Y, Kawatani M, Simizu S, Tanaka T, Takada M, Imoto M (2000) Bcl-2-independent induction of apoptosis by neuropeptide receptor antagonist in human small cell lung carcinoma cells. Anticancer Res 20:3123–3129PubMedGoogle Scholar
  6. 6.
    Danesi R, Del Tacca M (1996) The effects of the somatostatin analog octreotide on angiogenesis in vitro. Metabolism 45:49–50PubMedCrossRefGoogle Scholar
  7. 7.
    Woltering EA, Barrie R, O’Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J (1991) Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 50:245–251PubMedCrossRefGoogle Scholar
  8. 8.
    Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389–427PubMedCrossRefGoogle Scholar
  9. 9.
    Janin YL (2003) Peptides with anticancer use or potential. Amino Acids 25:1–40PubMedGoogle Scholar
  10. 10.
    Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G (2004) New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 61:1042–1068PubMedCrossRefGoogle Scholar
  11. 11.
    Frucht H, Gazdar AF, Park JA, Oie H, Jensen RT (1992) Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells. Cancer Res 52:1114–1122PubMedGoogle Scholar
  12. 12.
    Cancer Facts and Figures 2004, American Cancer Society, Inc, ©2004Google Scholar
  13. 13.
    Kennedy BJ (1964) Chemotherapy of colon cancer. J Lancet 84:131–133PubMedGoogle Scholar
  14. 14.
    Andre T, Louvet C, De Gramont A (2004) Colon cancer: what is new in 2004? Bull Cancer 91:75–80PubMedGoogle Scholar
  15. 15.
    Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A, Preusser P (2004) New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100:1558–1577PubMedCrossRefGoogle Scholar
  16. 16.
    Mukherjee R, Jaggi M (2000). Drug for treatment of cancer. US Patent 6,156,725Google Scholar
  17. 17.
    Singh H, Kumar A, Courtney M, Townshed JR, Samad Z, Singh, PA (1988) A Synthetic peptide, L-8-K, and its antibody both inhibit the specific binding of vasoactive intestinal peptide to hamster pancreatic cancer cells. Ann NY Acad Sci 527:679–681CrossRefGoogle Scholar
  18. 18.
    Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT (2003). Substance P analogs for the treatment of cancer. US Patent 6,596,692Google Scholar
  19. 19.
    Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Mathur A (2001) Somatostatin analogs for the treatment of cancer. US Patent 6,316,414Google Scholar
  20. 20.
    Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Mathur A. Bombesin analogs for the treatment of cancer. US Patent appl. 09/630,999Google Scholar
  21. 21.
    Cuttitta F, Carney DN, Mulshine J, Moody TW, Fedorko J, Fischler A, Minna JD (1985) Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature 316:823–826PubMedCrossRefGoogle Scholar
  22. 22.
    Rozengurt E (1990) Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events. Am Rev Respir Dis 142:S11–S15PubMedGoogle Scholar
  23. 23.
    Aprikian AG, Tremblay L, Han K, Chevalier S (1997) Bombesin stimulates the motility of human prostate-cancer cells via the tyrosine phosphorylation of focal adhesion kinase and integrin-associated proteins. Int J Cancer 72:498–504PubMedCrossRefGoogle Scholar
  24. 24.
    Gugger M, Reubi JC (1999) Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155:2067–2076PubMedGoogle Scholar
  25. 25.
    Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59:1152–1159PubMedGoogle Scholar
  26. 26.
    Cai RZ, Reile H, Armatis P, Schally AV (1994) Potent Bombesin Antagonists with C-Terminal Leu-(CH2-N)-Tac-NH2 or its derivatives. Proc Natl Acad Sci U S A 91:12664–12668PubMedCrossRefGoogle Scholar
  27. 27.
    Coy DH, Taylor JE, Jiang NY, Kim SH, Wang LH, Huang SC, Moreau JP, Gardner JD, Jensen RT (1989) Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. J Biol Chem 264:14691–14697PubMedGoogle Scholar
  28. 28.
    Mantey SA, Coy DH, Entsuah LK, Jensen RT (2004) Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3. J Pharmacol Exp Ther 310:1161–1170PubMedCrossRefGoogle Scholar
  29. 29.
    Zachary I, Rozengurt E (1986) A substance P antagonist also inhibits specific binding and mitogenic effects of vasopressin and bombesin-related peptides in Swiss 3T3 cells. Biochem Biophys Res Commun 137:135–141PubMedCrossRefGoogle Scholar
  30. 30.
    Woll PJ, Rozengurt E (1988) D-Arg1,D-Phe5,D-Trp7,9,Leu11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro. Proc Natl Acad Sci U S A 85:1859–1863PubMedCrossRefGoogle Scholar
  31. 31.
    Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C (2003) Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999–1017PubMedCrossRefGoogle Scholar
  32. 32.
    Scarpignato C, Pelosini I (2001) Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 47:1–29PubMedCrossRefGoogle Scholar
  33. 33.
    Janecka A, Zubrzycka M, Janecki T (2001) Somatostatin analogs. J Pept Res 58:91–107PubMedCrossRefGoogle Scholar
  34. 34.
    Karle IL, Balaram P (1990) Structural characteristics of alpha-helical peptide molecules containing Aib residues. Biochemistry 29:6747–6756PubMedCrossRefGoogle Scholar
  35. 35.
    Karle IL, Gurunath R, Prasad S, Kaul R, Rao BR, Balaram P (1995) Peptide design. Structural evaluation of potential nonhelical segments attached to helical modules. J Am Chem Soc 117:9632–9637CrossRefGoogle Scholar
  36. 36.
    Prasad S, Rao BR, Balaram P (1995) Contrasting solution conformations of peptides containing a, a-dialkylated residues with linear and cyclic side chains. Biopolymers 35:11–20PubMedCrossRefGoogle Scholar
  37. 37.
    Prasad S, Rao RB, Bergstrand H, Lundquist B, Becker EL, Balaram P (1996) Conformation-activity correlations for chemotactic tripeptide analogs incorporating dialkyl residues with linear and cyclic sidechains at position 2. Int J Pept Protein Res 48:312–318PubMedCrossRefGoogle Scholar
  38. 38.
    Kazmierski W, Wire WS, Lui GK, Knapp RJ, Shook JE, Burks TF, Yamamura HI, Hruby VJ (1988) Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors. J Med Chem 31:2170–2177PubMedCrossRefGoogle Scholar
  39. 39.
    Jaggi M, Mukherjee R (1992) A modified colorimetric assay (MTT) for testing cytotoxicity of anti cancer drugs on primary tumor cells. Anticancer Res 12(6B):2340Google Scholar
  40. 40.
    Mukherjee R, Jaggi M. Method for establishing a tumor-cell line by preparing single-cell suspension of tumor cells from tumor biopsies. US Patent 5744363Google Scholar
  41. 41.
    Jaggi M, Mukherjee R (1992) Experimental approaches to establishment of primary cultures of adenocarcinoma cells and their in vivo transfer for tumor formation to test anticancer drugs. Anticancer Res 12(6A)Google Scholar
  42. 42.
    Jaggi M, Mukherjee R (1994) New, sensitive and specific ELISA for the detection of neuropeptides in culture supernatants. J Immunoass 15:129–146CrossRefGoogle Scholar
  43. 43.
    Quin JA, Sgambati SA, Goldenring JR, Basson MD, Fielding LP, Modlin IM, Ballantyne GH (1995) PYY inhibition of VIP-stimulated ion transport in the rabbit distal ileum. J Surg Res 58:111–115PubMedCrossRefGoogle Scholar
  44. 44.
    Mukherjee R, Doval DC, Raghunadharao D, Majumdar A, Ganguly S, Jaggi M, Prasad S, Singh AT Burman AC (2003) Phase I dose escalating study of DRF7295: a new class of peptide based drugs. ASCO, Abstract ID: 948Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Manu Jaggi
    • 1
    Email author
  • Sudhanand Prasad
    • 1
  • Anu T. Singh
    • 1
  • R. Praveen
    • 1
  • Sarjana Dutt
    • 1
  • Archana Mathur
    • 1
  • Rajan Sharma
    • 1
  • Neena Gupta
    • 1
  • Rinku Ahuja
    • 1
  • Rama Mukherjee
    • 1
  • Anand C. Burman
    • 1
  1. 1.Dabur Research FoundationGhaziabadIndia

Personalised recommendations